Abstract
Type 2 diabetes is reaching epidemic proportions. Therapeutic maintenance of strict glycaemic control limits the risk of microvascular (retinopathy, nephropathy, and neuropathy) and macrovascular complications, 1 Holman RR Paul SK Bethel MA Matthews DR Neil HA 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359: 1577-1589 Crossref PubMed Scopus (5150) Google Scholar and treatment of diabetes also requires aggressive intervention against dyslipidaemia, hypertension, and excessive weight. 2 Gaede P Lund-Andersen H Parving HH Pedersen O Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008; 358: 580-591 Crossref PubMed Scopus (2753) Google Scholar Yet only about 40% of type 2 diabetic patients reach target glycaemia with standard therapies (eg, metformin, sulphonylurea, and insulin). Moreover, many antihyperglycaemic drugs induce hypoglycaemia, weight gain, or both. Weight gain is undesirable because about 85% of type 2 diabetic patients are overweight or obese, which could worsen cardiovascular risk. 3 Van Gaal LF Mertens IL De Block CE Mechanisms linking obesity with cardiovascular disease. Nature. 2006; 444: 875-880 Crossref PubMed Scopus (1988) Google Scholar Therefore, efficacious new antidiabetic agents without serious side-effects are highly desirable. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)Liraglutide once a day provided significantly greater improvements in glycaemic control than did exenatide twice a day, and was generally better tolerated. The results suggest that liraglutide might be a treatment option for type 2 diabetes, especially when weight loss and risk of hypoglycaemia are major considerations. Full-Text PDF
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
